Oruka Therapeutics, Inc.
ORKA
$111.04
$2.922.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.02% | 7.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.53% | 5.82% | |||
| Operating Income | -37.53% | -5.82% | |||
| Income Before Tax | -29.50% | -7.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.50% | -7.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.50% | -7.56% | |||
| EBIT | -37.53% | -5.82% | |||
| EBITDA | -37.57% | -5.78% | |||
| EPS Basic | -16.07% | -6.34% | |||
| Normalized Basic EPS | -13.62% | -6.09% | |||
| EPS Diluted | -16.07% | -6.34% | |||
| Normalized Diluted EPS | -13.62% | -6.09% | |||
| Average Basic Shares Outstanding | 13.96% | 1.38% | |||
| Average Diluted Shares Outstanding | 13.96% | 1.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||